📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
3 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
NEUTRAL
TOTAL VIEWS
7
RECENT COVERAGE · 3 ARTICLES
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Calidi Biotherapeutics announced the appointment of Corsee Sanders, a veteran biotech executive with 30+ years at major pharmaceutical...
Legend Biotech Corporation Announces Proposed Public Offering
LEGN announced a $225 million underwritten public offering of American Depositary Shares, with underwriters granted a 30-day option to...
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Legend Biotech announced Phase 1 clinical proof-of-concept for LB2501, an in vivo dual-targeting CAR-T therapy designed to treat...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice